Vol. 5 No. 10 (2025)
Reimbursement Reviews

Pasireotide (Signifor LAR)

decorative image of the issue cover

Published October 29, 2025

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses pasireotide for injectable suspension (Signifor LAR), 40 mg and 60 mg vial; deep intramuscular injection.
  • Indication: For the treatment of adult patients with acromegaly for whom surgery is not an option or has not been curative.